{"id":400887,"date":"2020-12-16T08:33:33","date_gmt":"2020-12-16T13:33:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400887"},"modified":"2020-12-16T08:33:33","modified_gmt":"2020-12-16T13:33:33","slug":"abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/","title":{"rendered":"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>ABP 300 is a novel human antibody therapy that\u00a0has been shown to\u00a0neutralize\u00a0COVID-19 in preclinical\u202f<\/em>in vivo<em>\u202fstudies<\/p>\n<p><\/em><\/li>\n<li>\n          <em>Pivotal\/Registrational studies will assess<\/em><br \/>\n          <em>safety, tolerability, efficacy, and pharmacokinetics <\/em><br \/>\n          <em>of ABP300 in approximately 2,000 subjects<\/em><br \/>\n          <em>\u202f\u00a0<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">WOBURN, Mass., Dec.  16, 2020  (GLOBE NEWSWIRE) &#8212; Abpro\u00a0Corporation today announced the initiation of global Phase 2\/3 registrational studies evaluating the safety, tolerability, efficacy, and pharmacokinetics of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV2 infection. The first trial site has been opened with the remainder to follow in 2021. The Phase 1 clinical trial, which included 42 subjects, study results are expected in Q1 2021.<\/p>\n<p align=\"justify\">\u201cThe initiation of global pivotal studies of ABP300 is a significant milestone for our company. It comes at a critical time as mankind battles another wave of COVID-19 and hospitalizations continue to rise,\u201d said Ian Chan, chief executive officer of Abpro. \u201cNeutralizing antibodies have not only demonstrated efficacy as a first line therapy for newly diagnosed COVID-19 patients but are well positioned to serve as the main therapy for patients who do not receive, or do not respond to COVID-19 vaccines. We feel this is especially true of our antibody drug candidate, which based on non-human primate and clinical in-human safety data, holds promise for effective COVID-19 treatment, and we look forward to reporting data from this study in Q1 2021.\u201d<\/p>\n<p align=\"justify\">ABP 300 is a novel human antibody therapy that neutralizes COVID-19 by binding to the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein, blocking the viral interaction with the angiotensin-converting enzyme 2 (ACE2) receptors of host which are critical for viral entry and infection. Through this mechanism of action, ABP 300 not only completely neutralizes COVID-19 in animal models but could potentially do so more safely and more\u00a0effectively\u00a0than other monoclonal antibodies already approved and in clinical development.\u00a0A study validating the efficacy of ABP300\u2019s mechanism of action in non-human primate models was recently published in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gQXVx2JSlb5lTKcvH1S7WsZkwZShwUqLtdbpS-fwu77i9C9RT9AVWLebrktIF2vIfrPSvIKPrOdjZw72Jq3DT1o7a7_X9R4azujeqvWY4fhCH3yLel8CW1UWBDg3eknF\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><em>Nature Communications<\/em><\/a><em>. <\/em>This is one of the only studies of its kind demonstrated in the industry to date.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">The Phase 2\/3 will include a series of studies, including a global, multicenter, randomized, double-blind, placebo-controlled, pivotal registrational clinical trial of monoclonal antibody ABP 300 for the early treatment of patients with mild or moderate COVID-19. ABP 300 will be delivered in a one-time dose across 3 treatment arms using a 1:1:1 randomization comparing a high dose, low dose, and placebo.<\/p>\n<p align=\"justify\">ABP 300 was\u00a0developed to confer design features that potentially allow for more potent viral neutralization, higher efficacy against a larger number of strains, and enhanced safety benefits due to reduced antibody dependent enhancement (ADE), a\u00a0potential\u00a0adverse side effect of monoclonal antibody therapies.<\/p>\n<p align=\"justify\">\n        <strong>About ABP 300<\/strong>\u00a0<br \/>\u202f\u00a0<br \/>ABP 300 is a human neutralizing monoclonal antibody therapy against COVID-19\u00a0that\u00a0was\u00a0created using the latest technologies available for antibody discovery. It was isolated from a patient who recovered from COVID-19 and engineered for highest safety and efficacy. ABP 300\u00a0disrupts the interaction of\u00a0the viral\u00a0receptor binding domain (RBD) with\u00a0host\u00a0angiotensin-converting enzyme 2 (ACE2)\u00a0receptor\u00a0and\u00a0has shown neutralizing efficacy\u202f<em>in vivo<\/em>\u202fagainst COVID-19\u00a0by blocking viral entry into cells. Data has been published in <em>Nature Communications<\/em>. ABP 300 is currently being studied in Phase 2\/3 global registrational studies in patients with COVID-19.\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About Abpro<\/strong>\u00a0<br \/>\u202f\u00a0<br \/>Abpro Corporation is a clinical stage biotechnology company located in Woburn, Massachusetts. The Company\u2019s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro\u2019s Diversimmune\u2122\u202fplatform has been used successfully to generate monoclonal antibodies against 300 traditionally difficult targets. The Diversimmune\u2122\u00a0platform combines the latest in nano-immunology, next-generation sequencing, advanced engineering and bioinformatics to create monoclonal antibodies against traditionally difficult targets. The Company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas. For more information, please visit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kRlser5w7Dy6JOZ-YpO9Bly8yGqE6NpHuvjE-tK48F2-JkSIF5dafmlk8yHv-FDm80IWB6ae3sGtG0_VTBRYjA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.abpro.com<\/u><\/a>.\u202f\u00a0<\/p>\n<p>\n        <strong>Media Contact<\/strong>\u00a0<br \/>Michael\u00a0Tattory\u00a0<br \/>LifeSci\u00a0Communications\u00a0<br \/>1 (646) 751-4362\u00a0<br \/><strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5IOQVeiyZb94VnCuZodNt0L4uu7mPycZb2LW8H_9QWtTmvR-iPSapfnQAvzPaqfm2L13yjypqPvtMKor9d-xY4v-rf5YbJ7k4AxRNVobMqw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mtattory@lifescicomms.com<\/a><\/u><\/strong><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/fb884a26-1d28-4cd7-ba7c-1abfec71c7d3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ABP 300 is a novel human antibody therapy that\u00a0has been shown to\u00a0neutralize\u00a0COVID-19 in preclinical\u202fin vivo\u202fstudies Pivotal\/Registrational studies will assess safety, tolerability, efficacy, and pharmacokinetics of ABP300 in approximately 2,000 subjects \u202f\u00a0 WOBURN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Abpro\u00a0Corporation today announced the initiation of global Phase 2\/3 registrational studies evaluating the safety, tolerability, efficacy, and pharmacokinetics of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV2 infection. The first trial site has been opened with the remainder to follow in 2021. The Phase 1 clinical trial, which included 42 subjects, study results are expected in Q1 2021. \u201cThe initiation of global pivotal studies of ABP300 is a significant &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400887","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ABP 300 is a novel human antibody therapy that\u00a0has been shown to\u00a0neutralize\u00a0COVID-19 in preclinical\u202fin vivo\u202fstudies Pivotal\/Registrational studies will assess safety, tolerability, efficacy, and pharmacokinetics of ABP300 in approximately 2,000 subjects \u202f\u00a0 WOBURN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Abpro\u00a0Corporation today announced the initiation of global Phase 2\/3 registrational studies evaluating the safety, tolerability, efficacy, and pharmacokinetics of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV2 infection. The first trial site has been opened with the remainder to follow in 2021. The Phase 1 clinical trial, which included 42 subjects, study results are expected in Q1 2021. \u201cThe initiation of global pivotal studies of ABP300 is a significant &hellip; Continue reading &quot;Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T13:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abpro Announces Initiation of Phase 2\\\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19\",\"datePublished\":\"2020-12-16T13:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/\"},\"wordCount\":656,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/\",\"name\":\"Abpro Announces Initiation of Phase 2\\\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==\",\"datePublished\":\"2020-12-16T13:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abpro Announces Initiation of Phase 2\\\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19 - Market Newsdesk","og_description":"ABP 300 is a novel human antibody therapy that\u00a0has been shown to\u00a0neutralize\u00a0COVID-19 in preclinical\u202fin vivo\u202fstudies Pivotal\/Registrational studies will assess safety, tolerability, efficacy, and pharmacokinetics of ABP300 in approximately 2,000 subjects \u202f\u00a0 WOBURN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Abpro\u00a0Corporation today announced the initiation of global Phase 2\/3 registrational studies evaluating the safety, tolerability, efficacy, and pharmacokinetics of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV2 infection. The first trial site has been opened with the remainder to follow in 2021. The Phase 1 clinical trial, which included 42 subjects, study results are expected in Q1 2021. \u201cThe initiation of global pivotal studies of ABP300 is a significant &hellip; Continue reading \"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T13:33:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19","datePublished":"2020-12-16T13:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/"},"wordCount":656,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/","name":"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==","datePublished":"2020-12-16T13:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4MiMzODgzOTA2IzUwMDA3NTA5OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-initiation-of-phase-2-3-registrational-studies-of-its-neutralizing-antibody-therapeutic-abp-300-for-the-treatment-of-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abpro Announces Initiation of Phase 2\/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400887"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400887\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}